Why BlueJay Diagnostics Stock Is Falling
Why BlueJay Diagnostics Stock Is Falling
Bluejay Diagnostics, Inc. (NASDAQ:BJDX) shares are trading lower Thursday after the company announced the pricing of a $3.5 million public offering.
Bluejay Diagnostics, Inc.（納斯達克股票代碼：BJDX）週四股價走低，此前該公司宣佈了350萬美元公開募股的定價。
The Details:
細節：
BlueJay Diagnostics announced the public offering of 2,692,308 shares at $1.30 per share. The gross proceeds from the offering are expected to be approximately $3.5 million, and BlueJay Diagnostics intends to use the proceeds to fund matters related to obtaining FDA approval, other research and development activities and for general working capital needs.
BlueJay Diagnostics宣佈以每股1.30美元的價格公開發行2692,308股股票。此次發行的總收益預計約爲350萬美元，BlueJay Diagnostics打算將所得款項用於資助與獲得美國食品藥品管理局批准、其他研發活動以及一般營運資金需求有關的事項。
On Wednesday, the company announced the initiation of a multicenter clinical study to evaluate the Symphony IL-6 test in sepsis patients.
週三，該公司宣佈啓動一項多中心臨床研究，以評估敗血症患者的Symphony IL-6測試。
BlueJay Diagnostics shares are falling on heavy trading volume following the announcement of a public offering. According to data from Benzinga Pro, more than 447,000 shares have been traded in the session, compared to the stock's 100-day average of less than 26,000 shares.
宣佈公開發行後，由於交易量龐大，BlueJay Diagnostics的股價正在下跌。根據Benzinga Pro的數據，該交易日已有超過44.7萬股股票的交易，而該股的100天平均交易量不到26,000股。
BlueJay Diagnostics shares are trading below the stock's 50-day moving average of $3.29 and well-below its 52-week high of $17.60.
BlueJay Diagnostics的股票交易價格低於該股的50天移動平均線3.29美元，遠低於其52周高點17.60美元。
Related News: Why Coherus BioSciences Stock Is Climbing Today
相關新聞：爲什麼 Coherus BioSciences 股票今天上漲
BJDX Price Action: According to Benzinga Pro, BlueJay Diagnostics shares are down 29% at $1.24 at the time of publication.
BJDX價格走勢：根據Benzinga Pro的數據，BlueJay Diagnostics的股價在發佈時下跌了29％，至1.24美元。
Image: Mohamed Hassan from Pixabay
圖片：來自 Pixabay 的穆罕默德·哈桑
譯文內容由第三人軟體翻譯。